Article Text

Download PDFPDF
Original research
Association between primary hypothyroidism and metabolic dysfunction-associated steatotic liver disease: an updated meta-analysis
  1. Alessandro Mantovani1,
  2. Alessandro Csermely1,
  3. Josh Bilson2,
  4. Niccolò Borella1,
  5. Scoccia Enrico1,
  6. Barbara Pecoraro1,
  7. Emigela Shtembari1,
  8. Riccardo Morandin1,
  9. Stergios A Polyzos3,
  10. Luca Valenti4,
  11. Herbert Tilg5,
  12. Christopher D Byrne2,
  13. Giovanni Targher6,7
  1. 1Endocrinology and Metabolism, University of Verona Faculty of Medicine and Surgery, Verona, Italy
  2. 2Southampton General Hospital, Southampton, UK
  3. 3First Laboratory of Pharmacology, School of Medicine, Aristotle University of Thessaloniki Faculty of Health Sciences, Thessaloniki, Greece
  4. 4Department of Transfusion Medicine, Precision Medicine Lab, Biological Resource Center, IRCCS Cà Granda Ospedale Maggiore Policlinico, milano, Italy
  5. 5Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology & Metabolism, Medizinische Universitat Innsbruck, Innsbruck, Austria
  6. 6Metabolic Diseases Research Unit, IRCCS Sacro Cuore - Don Calabria Hospital, Negrar di Valpolicella (VR), Italy
  7. 7Department of Medicine, University of Verona Faculty of Medicine and Surgery, Verona, Italy
  1. Correspondence to Professor Giovanni Targher, Metabolic Diseases Research Unit, IRCSS Sacro Cuore - Don Calabria Hospital, Negrar di Valpolicella (VR), Italy; giovanni.targher{at}univr.it

Abstract

Objective Epidemiological studies have reported an association between primary hypothyroidism and metabolic dysfunction-associated steatotic liver disease (MASLD). However, the magnitude of the risk and whether this risk changes with the severity of MASLD remains uncertain. We performed a meta-analysis of observational studies to quantify the magnitude of the association between primary hypothyroidism and the risk of MASLD.

Design We systematically searched PubMed, Scopus and Web of Science from database inception to 31 January 2024, using predefined keywords to identify observational studies in which MASLD was diagnosed by liver biopsy, imaging or International Classification of Diseases codes. A meta-analysis was performed using random-effects modelling.

Results We identified 24 cross-sectional and 4 longitudinal studies with aggregate data on ~76.5 million individuals. Primary hypothyroidism (defined as levothyroxine replacement treatment, subclinical hypothyroidism or overt hypothyroidism) was associated with an increased risk of prevalent MASLD (n=24 studies; random-effects OR 1.43, 95% CI 1.23 to 1.66; I2=89%). Hypothyroidism was also associated with a substantially higher risk of metabolic dysfunction-associated steatohepatitis or advanced fibrosis (n=5 studies; random-effects OR 2.84, 95% CI 2.07 to 3.90; I2=0%). Meta-analysis of data from four longitudinal studies showed that there was a marginally non-significant association between hypothyroidism and risk of developing MASLD over a median 4.5-year follow-up (random-effects HR 1.39, 95% CI 0.98 to 1.97; I2=85%). Sensitivity analyses did not modify these findings. The funnel plot did not reveal any significant publication bias.

Conclusion This large and updated meta-analysis provides evidence that primary hypothyroidism is significantly associated with both an increased presence of and histological severity of MASLD.

  • meta-analysis
  • nonalcoholic steatohepatitis

Data availability statement

All data relevant to the study are included in the article or uploaded as online supplemental information.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Data availability statement

All data relevant to the study are included in the article or uploaded as online supplemental information.

View Full Text

Footnotes

  • X @lucavalenti75

  • Contributors AM and GT were involved in the conception of the study, the analysis and interpretation of the results and wrote the first draft of the manuscript. AC, NB, JB, BP, ES and RM were involved in the conduct of the study and searched the published articles. JB, SAP, LV, HT and CDB were involved in the interpretation of the results and contributed to the discussion. All authors edited, reviewed and approved the final version of the manuscript. GT is the guarantor of the study who accept full responsibility for the work and the conduct of the study, had access to the data and controlled the decision to publish.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.